Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate maintenance plus docetaxel after progression on abiraterone in metastatic castration-resistant prostate cancer
2013-003811-23Phase 2Completed
- Sponsor
- SOGUG
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by SOGUG. Primary endpoint: 12-month radiographic progression-free survival. Started Nov 2013; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-003811-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003811-23.